Abstracts Archive - Page 544 of 1683 - ATC Abstracts

2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
G. A. Böhmig¹, M. Dürr², B. Jilma³, F. Eskandary¹, E. Chong⁴, S. Schranz³, K. Doberer¹, M. Wahrmann¹, A. Borski¹, H. Regele⁵, J. Kläger⁵, R. Reindl-Schwaighofer¹, J. Reeve⁶, K. Budde², P. F. Halloran⁶
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Nephrology Department, Charité Berlin, Berlin, Germany, ³Dept. of Clin. Pharmacology, Medical University of Vienna, Vienna, Austria, ⁴Vitaeris Inc., Vancouver, BC, Canada, ⁵Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ⁶Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…
2020 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
D. Kumar¹, I. Yakubu¹, S. Paluri¹, A. Chachar¹, J. Chang², I. Moinuddin¹, L. Kamal¹, M. Levy¹, C. Bhati¹, A. King¹, P. Kimball¹, P. Halloran², G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²ATAGC, Edmonton, AB, Canada
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause kidney transplant (KT) loss. Current therapies have unclear efficacy and side effects. Basic and…
2020 American Transplant Congress
Gene Expression Signatures Associated with Antibody-Mediated Rejection (ABMR) in Renal Allograft Biopsies (Bx) Are Beneficial to Clarifying ABMR Activity in Ambivalent Cases
H. Zhang¹, C. C. Nast², N. Ammerman³, A. A. Vo³, I. Gallegos³, M. Arevalo³, S. C. Jordan³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: “Thoroughly validated gene transcripts” in renal Bx was adopted as one of the criteria for ABMR diagnosis in the latest Banff classification. Here, we…
2020 American Transplant Congress
Graft Survival after Liver Transplantation for Patients with Cholangiocarcinoma
I. A. Ziogas, L. A. Hickman, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. A. Rega, I. D. Feurer, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the treatment for unresectable cholangiocarcinoma (CCA), however, post-LT graft survival is not well described.…
2020 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. Tzakis², S. Nishida², H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²University of Miami, Miami, FL
*Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…
2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
K. Nunez, T. Sandow, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
2020 American Transplant Congress
Liver Transplantation for Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis of Survival Rates
I. A. Ziogas¹, K. P. Economopoulos², M. H. Hayat¹, L. K. Matsuoka¹, M. I. Montenovo¹, M. Izzy¹, S. P. Alexopoulos¹
¹Vanderbilt University Medical Center, Nashville, TN, ²Duke University Medical Center, Durham, NC
*Purpose: Liver transplant (LT) accompanied by neoadjuvant chemoradiation has emerged as the only curative option for unresectable cholangiocarcinoma (CCA). Although numerous centers have published their…
2020 American Transplant Congress
Prognostic Index of Circulating Tumor Cells for Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation
M. Chen¹, Z. Chen¹, X. Lin², W. Ju¹, X. He¹
¹Transplant Center, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Division of General Surgery, The Eastern Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Liver transplantation (LT) is an effective option for hepatocellular carcinoma (HCC) and end-stage liver cirrhosis. However, organ shortage and tumor recurrence are the main…
2020 American Transplant Congress
The Perioperative Coagulation Profile of Hepatocellular Carcinoma During Liver Transplantation Compared to Patients with Non-Malignant Disease: A Cause or Association for Decreased Blood Product Utilization During Liver Transplantation?
H. B. Moore, E. Pomfret, J. Pomposelli, C. Walker, R. Choudhury, H. Yaffe, M. Wachs, T. Bak, K. Conzen, M. Adams, T. Pshak, T. L. Nydam
University of Colorado, Aurora, CO
*Purpose: Hepatobiliary malignancies have been associated with hyper-coagulability. However, the impact of hepatocellular carcinoma (HCC) on coagulation during liver transplantation remains less clear. We hypothesize…
2020 American Transplant Congress
Predictors of Estimated GFR and Recurrent Chronic Kidney Disease (CKD) after Simultaneous Liver and Kidney Transplantation (SLKT): Results from the US Multicenter SKLT Consortium
P. Sharma¹, Z. Sui¹, M. Zhang¹, J. Magee¹, P. Barman², Y. Patel³, K. Walters⁴, S. Biggins⁵, A. Schluger⁶, G. Cullaro⁷, R. Wong⁸, J. Lai⁸, J. Jo⁹, J. Sinha⁹, L. VanWagner⁹, E. Verna⁷
¹Michigan Medicine, Ann Arbor, MI, ²UCSD, San Diego, CA, ³Duke, Durham, NC, ⁴UCLA, LA, CA, ⁵University of Washington, Seattle, WA, ⁶Westchester Medical Center, Weschester, NY, ⁷Columbia, New York, NY, ⁸UCSF, San Francisco, CA, ⁹Northwestern, Chicago, IL
*Purpose: SLKT is a life-saving intervention for patients with decompensated cirrhosis and concomitant end stage renal disease, irreversible acute kidney injury and select inherited metabolic…